Clinical Trial Update: A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update comparing two doses of EYE103 with ranibizumab (0.5 mg) in people with diabetic macular edema; the Phase 2/Phase 3 study is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• EYE103
• Ranibizumab (ranibizumab)

Snippet

Sponsor: EyeBiotech Ltd. | Conditions: Diabetic Macular Edema (DME) | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING